CPT code 81161 – DMD gene deletion and duplication analysis

Key takeaways

CPT code 81161 reports DMD gene deletion analysis, with duplication analysis included when the lab performs it.

81161 is a Tier 1 gene-specific code. Tier 2 levels (81400-81408) apply only where no Tier 1 code exists, such as full DMD sequencing under 81408.

ICD-10-CM G71.01 covers both Duchenne and Becker muscular dystrophy. G71.09 is for other dystrophies, such as distal or oculopharyngeal muscular dystrophy.

Most commercial payers require prior authorization before the specimen is collected, and a missing approval is a common denial cause.

Pabau, the practice management platform we build, submits 81161 claims through Claim.MD and posts remittances back to each charge.

CPT code 81161: Official descriptor and Tier 1 classification

CPT code 81161 is the Tier 1 molecular pathology code for deletion and duplication analysis of the DMD (dystrophin) gene.

Labs use it to confirm or rule out Duchenne and Becker muscular dystrophy, and to test at-risk female relatives for carrier status. The official descriptor in the American Medical Association CPT code set reads:

• DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy) deletion analysis, and duplication analysis, if performed.

That wording matters for billing. Deletion analysis is the required element, and duplication analysis is included only if the lab performs it. A deletion-only assay therefore still reports as 81161, and duplications never need a second code.

81161 sits in the molecular pathology section (81105-81479), inside the Tier 1 range of 81105-81383. Tier 1 holds about 100 gene-specific codes, each tied to one gene and one analytic method.

Tier 2 works differently. Codes 81400-81408 are nine resource-based complexity levels, Level 1 to Level 9, used only when no Tier 1 code exists for the analysis.

Exon count sets the level inside Tier 2, but it never moves a gene-specific code like 81161 out of Tier 1. Our guide to medical billing fundamentals covers where lab codes fit in the wider claim process.

What CPT code 81161 covers and what it excludes

CPT code 81161 covers copy number analysis across the whole DMD gene, on any validated platform. The descriptor names no technology. Multiplex Ligation-dependent Probe Amplification (MLPA), exon-level array comparative genomic hybridization (array CGH) and similar quantitative assays all report under the same code.

What 81161 includes:

• Deletion analysis across all 79 exons of the DMD gene, with duplication analysis when performed
• Testing on DNA from blood, saliva, muscle tissue or another validated specimen type
• Diagnostic testing in symptomatic patients, usually boys with proximal weakness or a raised creatine kinase (CK)
• Carrier testing in mothers, sisters and other at-risk female relatives

What 81161 excludes:

• Full DMD gene sequencing for point variants and small insertions or deletions: report 81408 (Tier 2, Level 9)
• Sequencing of one known familial sequence variant: report 81403, per variant exon
• Multigene neuromuscular panels that include DMD: report the matching panel code, or 81479 when none fits
• Dystrophin protein studies on muscle tissue, such as Western blot or immunostaining: these sit outside the molecular pathology codes

Dystrophin gene deletion/duplication analysis: How the procedure is performed

Dystrophin gene deletion/duplication analysis measures the copy number of each DMD exon to find missing or extra segments. Most labs run MLPA, which covers all 79 exons with two probe mixes. Array CGH with exon-level probes gives similar resolution and suits some lab workflows.

Deletion and duplication testing usually comes first, because large rearrangements explain most Duchenne and Becker cases. When it finds no deletion or duplication, labs often reflex to full gene sequencing under 81408.

Labs also report whether a deletion keeps or disrupts the reading frame. That finding helps clinicians predict a Duchenne or Becker course, and it informs eligibility for exon-skipping therapies.

CPT code 81161 vs 81408, 81403 and 81479: Choosing the right code

CPT 81161 applies whenever the lab analyzes the whole DMD gene for deletions, whatever the platform. Sequencing, known-variant testing and multigene panels each have their own code.

Billing 81479 when 81161 applies sends the claim to manual review and usually delays payment. The reverse, billing 81161 for a multigene panel, misstates the service and can be flagged on audit. The panel below sets the CPT choice next to the ICD-10 choice the same claim needs.

ICD-10 diagnosis codes to pair with CPT code 81161

The claim must carry an ICD-10-CM code that supports medical necessity. For a confirmed diagnosis, that code is G71.01, Duchenne or Becker muscular dystrophy. G71.01 is one combined code for both conditions, so a Becker patient takes G71.01 too. Check the CDC/NCHS ICD-10-CM web tool for current definitions and annual updates.

Outpatient coding never reports a suspected diagnosis as confirmed. Until the result is back, code the signs that prompted the test, such as weakness or a raised CK. Confirm the covered diagnosis list in your Medicare Administrative Contractor (MAC) Local Coverage Determination (LCD) before you submit.

Medicare coverage, LCD requirements, and eligible patient criteria

Medicare covers CPT code 81161 when the test is reasonable and necessary for a patient with signs of a dystrophinopathy. The rules come from the LCD of the MAC for the lab’s jurisdiction. Medicare does not pay for screening, so carrier testing without symptoms rarely meets its criteria.

Consistent insurance eligibility verification before the order keeps coverage problems off the claim. LCD criteria for DMD testing generally include:

• A documented clinical indication, such as progressive proximal weakness or a raised CK
• A result that will change how the patient is managed
• An ordering provider whose specialty fits the LCD, often neurology or medical genetics
• A performing lab with CLIA certification for molecular testing

Prior authorization requirements for CPT code 81161

Prior authorization rules depend on the payer, not on the code. Good medical billing compliance means checking each plan’s policy before the order is placed, not after the specimen is collected.

Medicare reimbursement rate for CPT code 81161

CPT code 81161 is paid under the CMS Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule. CLFS rates for established codes are based on private payer data reported under the Protecting Access to Medicare Act (PAMA). Rates update each January 1, so check the current national limitation amount before you set expectations.

Commercial allowables for 81161 depend on each lab’s contract and network status. Out-of-network labs can see steep reductions or outright denials, so confirm contract terms before testing.

Modifiers for CPT code 81161 and when to use them

CPT code 81161 is a lab code with no professional component, so modifiers 26 and TC do not apply on Medicare claims. A physician’s written interpretation is billed separately with G0452. Three modifiers come up more often.

Documentation requirements for DMD genetic testing billing

Documentation for CPT code 81161 has to show medical necessity before the order goes out. The claim record should hold these items:

• Ordering provider note: the clinical indication, exam findings and the specific test ordered
• CK result and family history: the evidence most LCDs and payer policies look for
• Methodology statement: the technology used, such as “MLPA with SALSA P034 and P035 probe mixes”
• Variant nomenclature: exon-level findings in HGVS format, such as “deletion of exons 45-50”
• Coverage statement: confirmation that the assay covered all 79 exons, not a subset
• Lab credentials: CLIA certification of the performing lab, plus CAP accreditation where a payer asks for it
• Authorization record: the PA number and date, recorded before the specimen is collected

A report missing the methodology or exon-level detail is a common trigger for records requests. Fix the report template once, and every later claim carries the right detail.

Top denial reasons for CPT code 81161 and how to fix them

CPT code 81161 claims fail for predictable reasons, and each one has a direct fix. A solid denial management workflow sorts denials by cause as they arrive, so patterns surface before they turn into write-offs.

Knowing the common denial codes in medical billing helps billing teams respond faster. It also shows whether a denial is correctable or needs a policy-level appeal.

Billing CPT 81161 with companion codes: G0452, genetic counseling and sequencing

G0452 is the HCPCS code for a physician’s interpretation and report of a molecular pathology procedure. The lab bills 81161 for the test itself, and the interpreting physician bills G0452 on a separate claim. Payers expect G0452 only when a physician adds clinical interpretation beyond the standard lab report.

Genetic counseling bills separately under 96041, which replaced 96040 on January 1, 2025. 96041 reports each 30 minutes of total counselor time on the date of the encounter. Pre-test and post-test sessions are common for Duchenne and Becker families, because carrier results affect other relatives.

When 81161 comes back negative and the lab reflexes to sequencing, 81408 goes on the claim as a separate service. Check NCCI edits and the payer’s reflex-testing policy before billing both on one date of service.

Always check the AAPC CPT code reference for current parenthetical notes and bundling guidance before you submit companion codes.

Billing workflow: Step-by-step claim submission for CPT 81161

A clean claim for CPT code 81161 depends on action at several points, from the test order to payment posting. Submitting clean claims from the start avoids the rework cycle that denied molecular pathology claims create.

1. Confirm the clinical indication and ordering provider: check that the provider meets the LCD specialty rules. Weakness, a raised CK or family history should support the diagnosis code.
2. Verify the payer’s PA requirement: check the current prior authorization policy for molecular tests. Requirements change, so don’t rely on last year’s answer.
3. Obtain PA if required: submit the request with the clinical rationale, CPT code 81161, and G71.01 for a confirmed Duchenne or Becker diagnosis. For a suspected case, use the presenting sign codes, and record the PA number before specimen collection.
4. Perform the test and issue the report: include the methodology statement, exon-level findings in HGVS notation, and confirmation of full 79-exon coverage.
5. Select the CPT and ICD-10 codes: link G71.01 to CPT code 81161 for Duchenne or Becker muscular dystrophy. Add G0452 on a separate physician claim if the interpreting provider bills independently.
6. Attach the required documentation: include the signed requisition, the complete lab report and the PA approval number.
7. Submit the claim electronically through Claim.MD: Pabau’s Claim.MD clearinghouse integration scrubs the claim for errors and routes the 837P to the correct payer.
8. Track and respond to payer requests: watch the ERA (835 remittance) for documentation requests or partial payments, and respond within the payer’s timely filing window.

How Pabau keeps CPT 81161 claims documented and paid

DMD testing splits billing between two parties. The ordering practice holds the clinical notes, CK result and family history. The lab bills 81161, and its claim fails if that evidence never reaches it.

Pabau sends claims electronically through the Claim.MD clearinghouse. Its claims software for practices checks patient eligibility in real time before the order, then tracks each claim after submission. Remittances post back against the original charge, so a denial or underpayment shows up without a separate reconciliation.

The PA number, the lab report and the clinical notes sit in the same patient record. When a payer asks for records, your billing team sends them from one place instead of chasing the ordering practice.

Get CPT 81161 claims paid the first time

Pabau submits claims through Claim.MD, checks eligibility in real time, and posts remittances back to each charge. Your billing team can follow every 81161 claim without switching systems.

Book a demo

Conclusion

CPT code 81161 is a Tier 1 code with a narrow job: whole-gene deletion analysis of DMD, with duplication analysis if performed. Its costly errors are a Tier 2 or unlisted code in its place, Becker coded to G71.09, and a missing authorization. Settle all three at the order stage, and an 81161 claim rarely needs an appeal.

Pabau keeps eligibility checks, claim submission and remittance posting in one system. A weak 81161 claim gets caught before it costs you a filing window. Book a demo to see how Pabau handles molecular pathology billing from order to payment.

Continue your research

Need to understand how clearinghouse validation works? How a medical claims clearinghouse works explains the role clearinghouses play in CPT and ICD-10 validation before claims reach the payer.

Working through a high denial rate on lab claims? Revenue cycle management fundamentals covers the end-to-end workflow from order to payment that lab billing teams need to minimize write-offs.

Want to understand the 837P claim format for molecular pathology? 837 electronic claim file guide breaks down the 837P transaction structure and how it maps to CMS-1500 fields for lab submissions.

Frequently asked questions